Gastric helicobacter infection induces a Th2 phenotype but does not elevate serum cholesterol in mice lacking inducible nitric oxide synthase.
Persistent Helicobacter felis infection in (C57BL/6 x 129SvEv)F1 mice induces chronic gastritis. Expression of inducible nitric oxide synthase (iNOS) is upregulated in response to Helicobacter infection. In this study, 20 10-week-old iNOS-/- mice and 20 wild-type [(C57BL/6 x 129SvEv)F1] mice were infected with H. felis by oral gavage and were assessed histologically and serologically at 32 weeks postinfection. Equal numbers of uninfected controls were sham inoculated. The mice were scored for severity of gastric inflammation, hyperplasia, glandular atrophy, and mucous metaplasia in the corpus and for the level of helicobacter colonization. The immunoglobulin G1 (IgG1), IgG2a, and IgG2c antibody responses to H. felis were determined. As a secondary measure, serum cholesterol levels were assessed. iNOS-/- mice have a propensity for increased serum cholesterol, and although controversial, several human epidemiologic studies have demonstrated an association between Helicobacter infection and several risk factors for cardiovascular disease, including elevated serum cholesterol. Nevertheless, no differences in serum cholesterol levels were observed between the H. felis-infected and -uninfected iNOS-/- mice in this study. The uninfected animals had minimal to no gastric pathology. The gastric pathology scores for the infected animals were reduced significantly in the iNOS-deficient mice relative to those for the wild-type mice (all P <0.01). Helicobacter-infected iNOS-/- mice had chronic lymphoid infiltration and negligible to mild glandular atrophy and mucous metaplasia in the fundic mucosa, while H. felis-infected wild-type mice had severe atrophic and metaplastic mucosal changes. The atrophic gastritis in the infected wild-type mice, particularly the female mice, was also accompanied by greater granulocytic infiltration, antral hyperplasia, and diminished antral colonization, unlike that in the infected iNOS-/- mice. iNOS-/- mice developed significantly lower Th1-associated IgG2c antibody responses to H. felis (P <0.0003); the Th2-associated IgG1 responses were similar (P=0.09), suggesting a greater effect of the iNOS defect on Th1 responses. H. felis colonization was significantly greater in the iNOS-deficient mice. These findings are indicative of an impaired Th1 component of the H. felis-induced inflammatory response when the influence of iNOS is removed.
Ihrig
Melanie
M
Division of Comparative Medicine, Massachusetts Institute of Technology, 77 Massachusetts Ave., Bldg. 16, Rm. 825C, Cambridge, MA 02139, USA.
Whary
Mark T
MT
Dangler
Charles A
CA
Fox
James G
JG
D000818:Animals; D000907:Antibodies, Bacterial / Q000097:blood; D002784:Cholesterol / Q000097:blood*; D005260:Female; D005756:Gastritis / Q000097:blood / Q000276:immunology* / Q000382:microbiology / Q000473:pathology; D016481:Helicobacter Infections / Q000097:blood / Q000276:immunology* / Q000382:microbiology / Q000473:pathology; D044922:Helicobacter felis / Q000276:immunology / Q000472:pathogenicity*; D008297:Male; D051379:Mice; D008810:Mice, Inbred C57BL; D018345:Mice, Knockout; D019001:Nitric Oxide Synthase / Q000235:genetics* / Q000378:metabolism; D052247:Nitric Oxide Synthase Type II; D013047:Specific Pathogen-Free Organisms; D013270:Stomach / Q000382:microbiology / Q000473:pathology; D018418:Th2 Cells / Q000276:immunology*
D000907:Antibodies, Bacterial; D002784:Cholesterol; D019001:Nitric Oxide Synthase; D052247:Nitric Oxide Synthase Type II; C496317:Nos2 protein, mouse
J Biol Chem. 1999 Nov 19;274(47):33190-3
10559188
Free Radic Biol Med. 1999 Oct;27(7-8):781-9
10515582
Helicobacter. 2001 Mar;6(1):37-43
11328364
Dig Dis Sci. 2001 Apr;46(4):836-44
11330421
Atherosclerosis. 2001 May;156(1):103-7
11369002
Int Immunopharmacol. 2001 Aug;1(8):1397-406
11515807
Int Immunopharmacol. 2001 Aug;1(8):1407-20
11515808
Cancer Res. 2002 Feb 1;62(3):696-702
11830522
Infect Immun. 2002 Jun;70(6):3295-9
12011029
Mol Immunol. 2002 May;38(12-13):989-95
12009578
Helicobacter. 2002 Dec;7(6):342-8
12485120
Cancer Res. 2003 Mar 1;63(5):942-50
12615707
J Immunol. 2003 Apr 1;170(7):3782-9
12646644
Atherosclerosis. 2003 May;168(1):153-62
12732399
FEMS Immunol Med Microbiol. 2003 May 25;36(3):175-80
12738388
Dig Dis Sci. 2003 Apr;48(4):636-43
12741449
Biochem Pharmacol. 2003 May 15;65(10):1755-60
12754112
Aliment Pharmacol Ther. 2003 Jun;17 Suppl 2:75-81
12786617
Free Radic Biol Med. 2003 Jun 15;34(12):1621-30
12788482
Infect Immun. 2003 Jul;71(7):4163-6
12819109
Clin Biochem. 2003 Jul;36(5):359-65
12849867
J Pathol. 2003 Oct;201(2):303-11
14517848
Helicobacter. 2003;8(5):495-502
14535996
Curr Gastroenterol Rep. 2003 Dec;5(6):459-67
14602053
Am J Cardiol. 2004 Jan 15;93(2):219-20
14715353
Am J Physiol Gastrointest Liver Physiol. 2004 Mar;286(3):G361-6
14766534
Curr Top Med Chem. 2004;4(5):531-8
14965304
Gut. 2004 Sep;53(9):1250-5
15306579
Br Heart J. 1994 May;71(5):437-9
8011406
Gastroenterology. 1996 Jan;110(1):155-66
8536852
Immunology. 1997 Feb;90(2):205-11
9135548
Carcinogenesis. 1997 Sep;18(9):1841-5
9328184
BMJ. 1997 Nov 8;315(7117):1199-201
9393222
BMJ. 1998 Apr 11;316(7138):1130-2
9552950
J Biol Chem. 1998 Jun 5;273(23):14071-3
9603902
J Immunol Methods. 1998 Mar 15;212(2):187-92
9672206
Aliment Pharmacol Ther. 1998 Feb;12 Suppl 1:83-90
9701006
Nitric Oxide. 1998;2(3):187-92
9731636
Circulation. 1998 Sep 1;98(9):845-50
9738638
Circulation. 1998 Sep 29;98(13):1286-90
9751676
Atherosclerosis. 1999 Jan;142(1):207-10
9920523
Ann N Y Acad Sci. 1998 Nov 17;859:96-111
9928373
J Clin Microbiol. 1999 May;37(5):1651
10203549
Aliment Pharmacol Ther. 1999 Mar;13 Suppl 1:13-8
10209682
Clin Cancer Res. 1999 Jun;5(6):1411-5
10389926
J Immunol. 1999 Aug 1;163(3):1490-7
10415051
Age Ageing. 1999 Jul;28(4):367-71
10459790
Infect Immun. 1999 Oct;67(10):5151-6
10496889
Nat Med. 2000 May;6(5):536-42
10802709